The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ma, 2007, Myelodysplastic syndromes: incidence and survival in the United States, Cancer, 109, 1536, 10.1002/cncr.22570
Wang, 2011, Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes, Leuk Res, 35, 904, 10.1016/j.leukres.2010.10.007
Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8
Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792
Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B, J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117
Greenberg, 2008, The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines, J Natl Compr Canc Netw, 6, 942, 10.6004/jnccn.2008.0072
Silverman, 2006, Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, J Clin Oncol, 24, 3895, 10.1200/JCO.2005.05.4346
Steensma, 2009, Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial, J Clin Oncol, 27, 3842, 10.1200/JCO.2008.19.6550
Frytak, 2009, Estimation of economic costs associated with transfusion dependence in adults with MDS, Curr Med Res Opin, 25, 1941, 10.1185/03007990903076699
Warren, 2002, Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population, Med Care, 40, IV-3
Brown, 2002, Estimating health care costs related to cancer treatment from SEER-Medicare data, Med Care, 40, IV-104
Yabroff, 2008, Cost of care for elderly cancer patients in the United States, J Natl Cancer Inst, 100, 630, 10.1093/jnci/djn103
Wang, 2009, Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States, Cancer Causes Control, 20, 1369, 10.1007/s10552-009-9362-7
Wang, 2009, Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes, Leuk Res, 33, 1594, 10.1016/j.leukres.2009.02.005
Fenaux, 2010, Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C, Br J Haematol, 149, 244, 10.1111/j.1365-2141.2010.08082.x
Kantarjian, 2007, Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience, Cancer, 109, 1133, 10.1002/cncr.22508
Seymour, 2010, Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes, Crit Rev Oncol Hematol, 76, 218, 10.1016/j.critrevonc.2010.04.005
2000
Brown, 1999, Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer, Med Care, 37, 1249, 10.1097/00005650-199912000-00008
Warren, 2002, Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings, J Clin Oncol, 20, 307, 10.1200/JCO.20.1.307
Elixhauser, 1998, Comorbidity measures for use with administrative data, Med Care, 36, 8, 10.1097/00005650-199801000-00004
Lund, 2011, Identifying specific chemotherapeutic agents in medicare data: a validation study, Med Care
Surveillance Research Program. SEER*Stat software (seer.cancer.gov/seerstat) National Cancer Institute.
Rubin, 1997, Estimating causal effects from large data sets using propensity scores, Ann Intern Med, 127, 757, 10.7326/0003-4819-127-8_Part_2-199710151-00064
Griffiths, 2011, Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma, Blood, 118, 4808, 10.1182/blood-2011-04-348367
Goldberg, 2010, Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries, J Clin Oncol, 28, 2847, 10.1200/JCO.2009.25.2395
Cogle, 2011, Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries, Blood, 117, 7121, 10.1182/blood-2011-02-337964
Blum, 2010, How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes, Hematol Am Soc Hematol Educ Program, 2010, 314, 10.1182/asheducation-2010.1.314
Craig, 2011, Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes, Leuk Res, 35, 1453, 10.1016/j.leukres.2011.07.028